Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Valuation & Earnings
This table compares Syndax Pharmaceuticals and Insmed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Syndax Pharmaceuticals | $172.35 million | 4.56 | -$285.42 million | ($2.36) | -3.70 |
| Insmed | $606.42 million | 51.13 | -$1.28 billion | ($2.82) | -50.12 |
Syndax Pharmaceuticals has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Syndax Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Syndax Pharmaceuticals and Insmed, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
| Insmed | 1 | 1 | 23 | 1 | 2.92 |
Syndax Pharmaceuticals currently has a consensus price target of $41.40, indicating a potential upside of 374.23%. Insmed has a consensus price target of $196.52, indicating a potential upside of 39.05%. Given Syndax Pharmaceuticals’ higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Insmed.
Profitability
This table compares Syndax Pharmaceuticals and Insmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Syndax Pharmaceuticals | -72.32% | -804.38% | -34.93% |
| Insmed | -39.85% | -96.38% | -32.55% |
Summary
Insmed beats Syndax Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
